All of the regular ASCO abstracts dropped Thursday afternoon, with the biggest news coming from the VEGF bispecific race , Merck and Kelun-Biotech’s TROP2 ADC known as sac-TMT, and multiple head and neck cancer updates . But there were plenty of other developments across cancer trials and new mechanisms, and we’ve rounded up the best of the rest here. Find updates below on potential successors for Pfizer’s blockbuster Ibrance, the Tubulis data that got Gilead Sciences excited enough to buy it ou

→ Peter Griffith will be the second high-profile exec to leave Amgen this year when he retires on Sept. 1. Thomas Dittrich will replace him as CFO and return to Amgen in July. Dittrich handled CFO responsibilities at Swiss dermatology biotech Galderma and had an eight-year stint with Amgen, where he was VP, finance corporate planning and chief accounting officer from 2010-14. Like Dittrich at Galderma, Griffith joined Amgen in October 2019. As Endpoints News previously reported , technology chie

HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study Patient enrolment planned to begin by Q4 2026 Melbourne, Australia, May 19, 2026 (GLOBE

VADUZ, Liechtenstein, May 22, 2026 /PRNewswire/ -- Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStop® Significant events in the first quarter of 2026 Secured over EUR 1.2 million in new multi-year public tender approvals in Italy, further strengthening RefluxStop®'s commercial adoption and reimbursement position within the Italian national healthcare system Expanded the RefluxStop® Centers of Excellence network in Germany with the addition of Klinikum St. Georg in Leipzi

Migraine drug developer Mentari Therapeutics went public on Tuesday through a reverse merger with InMed Pharmaceuticals. Alongside the deal, Mentari secured $290 million in funding to extend its cash runway through 2028. "This transaction provides us with the capital and public market infrastructure to aggressively compete in what we believe will be the next era of migraine prevention," said Julie Bruno, chair of Mentari's board, in a company release.The biotech's co-lead assets are MT-001, an a

Novo Nordisk's Wegovy Pill wins key EMA panel endorsement Retro raises fresh funds at $1.8B valuationCVC joins forces with Groupe Bruxelles Lambert to bid €10.7B for RecordatiNovo Nordisk's Wegovy Pill wins key EMA panel endorsement The EMA's drug advisory panel on Friday recommended approval of Novo Nordisk's Wegovy Pill (semaglutide) for weight loss. The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) includes data on the GLP-1 drug's label from the Phase III SE

After reporting earlier this year that their personalised mRNA vaccine was linked to a nearly 50% recurrence-free survival (RFS) benefit in patients with high-risk melanoma, partners Merck & Co. and Moderna shared further five-year findings from the Phase IIb KEYNOTE-942 study in an abstract released ahead of the American Society of Clinical Oncology (ASCO) meeting. The data suggest that intismeran autogene (mRNA-4157), in combination with Merck's Keytruda (pembrolizumab), could help prolong RFS

As investors search for clues about whether the PD-(L)1/VEGF bispecific class can live up to the hype that was sparked by Akeso and Summit Therapeutics' ivonescimab two years ago, newly released abstracts ahead of the upcoming American Society of Clinical Oncology (ASCO) meeting shed some light on a pair of fast followers (see – Spotlight On: Lung cancer bispecifics poised to take centre stage at ASCO this year).BioNTech and Bristol Myers Squibb offered the first substantial look at their conten

An AI-based tool may help identify which patients with multiple myeloma are most likely to benefit from immunotherapy and stem cell transplantation by detecting immune-related signals hidden in routine bone marrow biopsy slides. The findings, set to be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting, could support more personalised treatment strategies for newly diagnosed patients.  Treatment options for the blood cancer have seen rapid growth in recent years, rang

French biotech OSE Immunotherapeutics said Friday that its cancer vaccine Tedopi (OSE2101) may help slow disease progression in patients with recurrent ovarian cancer when used alongside Merck & Co.'s Keytruda (pembrolizumab).Topline results from the Phase II TEDOVA study, slated for presentation at the upcoming American Society of Clinical Oncology (ASCO) meeting, offer a promising signal in a setting where treatment options remain limited after PARP inhibitors and bevacizumab, according to Ale